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Introduction: This study aimed to assess the safety of high doses of 
radiation delivered with tomotherapy to the intact lung after radical 
pleurectomy/decortication or biopsy for malignant pleural mesothe-
lioma (MPM).
Methods: Twenty-eight patients were enrolled in this prospective 
study and underwent adjuvant or definitive tomotherapy after radi-
cal pleurectomy/decortication (n = 20) or pleural biopsy (n = 8) for 
MPM. The dose prescribed to the planning target volume, defined 
as the entire hemithorax, including chest-wall incisions and drain 
sites and excluding the intact lung, was 50 Gy delivered in 25 frac-
tions. All patients underwent fluorodeoxyglucose-positron emission 
tomography for staging after surgery. Any fluorodeoxyglucose-avid 
areas or regions of particular concern for residual disease were given 
a simultaneous boost of radiotherapy to 60 Gy. Specific lung dosimet-
ric parameters were reported. Toxicity was graded using the modified 
Common Toxicity Criteria version 3.0.
Results: The median follow-up was of 19 months (range, 6–29 
months). Five patients (17.8%) experienced severe respiratory symp-
toms corresponding to grade 2 pneumonitis in three cases, and grade 
3 pneumonitis in two cases. No fatal respiratory toxicity was reported. 
Controlateral lung V5 was strongly correlated with the risk of pneumo-
nitis. Patients who developed grade 2 and 3 pneumonitis had a higher 
controlateral lung V5 (mean V5=32%) than those without pneumonitis 
(mean V5=17%) (p=0.002). Other two grade 3 toxicities were registered: 
one severe pain to the chest wall, and one severe thrombocytopenia.
Conclusions: Tomotherapy allows the safe delivery of high dose of 
radiation to the hemithorax of MPM patients with intact lung.
Key Words: Malignant pleural mesothelioma, Radiotherapy, 
Pneumonitis, Pleurectomy/decortication.
(J Thorac Oncol. 2012;7: 1862–1866)
Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura, mainly related to asbestos expo-
sure. Extrapleural pneumonectomy (EPP) represents a highly 
invasive surgical option, consisting of an en bloc removal of 
the lung, visceral and parietal pleura, hemipericardium, and 
diaphragm.1 Therefore, EPP has fallen out of favor among 
some surgeons, given the severe perioperative stress, the 
noticeable complication rate, and the long-term decrease in 
performance status. Radical pleurectomy/decortication (P/D) 
is a lung-sparing surgery for MPM, which represents a cyto-
reductive treatment option with the aim to remove all gross 
disease and to achieve macroscopic complete resection.2 This 
operation includes macroscopic removal of the parietal and 
visceral pleural layer, along with the pericardium and dia-
phragm if needed, yet sparing the underlying lung. After both 
procedures in most cases, residual disease is possibly left 
behind, and adjuvant radiation therapy emerges as the thera-
peutic strategy that is advocated.
Although it has been shown that it is feasible to deliver 
high-radiation doses with intensity-modulated radiotherapy 
(IMRT) after EPP,3 the use of adjuvant hemithoracic irradia-
tion after radical P/D is limited because of the difficulty of 
irradiating such a large target volume to high-radiation doses 
without exceeding the tolerance of the adjacent normal tis-
sues, especially the ipsilateral intact lung.4
Helical tomotherapy is a novel technique that allows the 
delivering of image-guided IMRT by using a dynamic deliv-
ery in which gantry, treatment couch, and multileaf collimator 
leaves are all in motion during treatment, resulting in a highly 
conformal radiation-dose distribution.5
We used helical tomotherapy to deliver high radia-
tion doses in MPM patients who underwent lung-sparing 
surgery, including radical P/D or biopsy. In this article we 
report dosimetric results and toxicity, with the purpose of 
assessing the safety of tomotherapy in MPM patients with 
intact lung.
METHODS AND MATERIALS
This prospective study was conducted with the approval 
of our Institutional Review Board, and written informed con-
sent was obtained from all the patients.
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Between January 2009 and June 2011, thirty-five 
patients were treated with radical P/D or had a pleural biopsy 
for an MPM, and underwent adjuvant or definitive radiother-
apy. Seven patients were excluded from the study because 
they were being treated with palliative radiation doses. The 
analysis was then conducted on 28 patients.
The radiation oncologist drew the clinical target volume 
(CTV) from the lung apex to upper abdomen to include all 
areas of preoperative pleural surfaces. Interlobar pleura were 
not included in the CTV. Volumes also included the ipsilateral 
mediastinal lymph nodes in case of pathological N1–2 disease. 
Thoracotomy scars were also included in the CTV. Particular 
attention was directed to defining the posterior/inferior extent of 
the CTV to include the insertion of the diaphragm, which was 
often in the vicinity of the L2 vertebral body. Medially, the CTV 
included the ipsilateral pericardium. Boost gross tumor volume 
was targeted on areas with positive margins or suspected residual 
disease, and foci of PET uptake on the restaging PET/CT done 
before radiation therapy. Boost gross tumor volume was defined 
together with the nuclear physician, for a better interpretation of 
PET imaging. Planning target volume (PTV) was delineated by 
uniform margins of 5 mm around the CTV. Normal tissue organs 
including liver, heart, esophagus, kidneys, ipsilateral and con-
tralateral lung, gastrointestinal tract, and spinal cord were also 
contoured. A dummy structure, representing the central part of 
the treated lung, was also defined, helping optimization of plan-
ning. This is defined as the lung parenchyma located more than 
2 cm internal to the pleural surface (Fig. 1).
The dose prescribed to the PTV was 50 Gy delivered 
in 25 fractions (2 Gy/fraction). Any fluorodeoxyglucose-avid 
areas or regions of particular concern for residual disease 
were given a simultaneous boost of radiotherapy to 60 Gy (2.4 
Gy/fraction). Radiotherapy boost was delivered in 25 patients.
 The spinal cord, ipsilateral and contralateral kidney, 
contralateral lung and the dummy structure were the dose-
limiting tissues. Specific dosimetric guidelines were the fol-
lowing: spinal cord maximum dose less than 45 Gy; ipsilateral 
and contralateral kidney V25 (percentage of kidney volume 
receiving 25 Gy) less than 40% and V10 less than 10%, 
respectively; liver V30 less than 40%; contralateral mean lung 
dose less than 7 Gy; dummy structure mean dose less than 36 
Gy. No specific dosimetric constraints were required for ipsi-
lateral lung or total lung.
Dose-volume histograms were generated for all relevant 
structures for each of the 28 plans. Specific metrics were cho-
sen to report dosimetric data in terms of dose distribution to 
the organs at risk.
Treatment was delivered once a day, five fractions 
weekly. All patients were treated by helical tomotherapy, a 
novel technique that allows the delivering of image-guided 
IMRT, resulting in a highly conformal radiation dose deliv-
ered. A megavolt CT-scan was also performed daily for each 
patient to image-guide the radiation treatment. All patients 
were administered inhalation steroids (Budesonide) during all 
the radiation course and antibiotics (Amoxicillin-Clavulanate) 
for 14 days (days 10–24), preventively.
Patients were seen weekly during the radiotherapy 
course, and then at regular intervals to determine the presence 
of symptoms. Physicians evaluated clinical symptoms by 
Common Toxicity Criteria of Adverse Events, version 3.0. 
Dosimetric parameters from the subgroups with and without 
grade 2 or greater pulmonary toxicity were compared using a 
two-tailed Student’s t test; statistical significance was claimed 
for p value less than 0.05.
RESULTS
Patients and tumor characteristics are listed in Table 
1. Twenty patients underwent radical P/D, with the resection 
of the entire parietal and visceral pleura, along with portions 
of the pericardium and diaphragm if involved by tumor, and 
mediastinal lymph adenectomy. Eight patients underwent 
pleural biopsy only. Twenty-seven patients received systemic 
chemotherapy, usually with the combination of pemetrexed 
and cisplatin. Of these, four patients received neoadjuvant 
chemotherapy before surgery, 17 received adjuvant chemo-
therapy, and six received both neoadjuvant and adjuvant che-
motherapy. The treatment profile is represented in Figure 2. 
Radiation was delivered 6 to 8 weeks after surgery or 4 weeks 
after completion of adjuvant chemotherapy.
The median follow-up was of 19 months (range, 6–29 
months). All patients had a minimum follow-up of 6 months 
and were assessable for acute radiotherapy-related toxicity.
There were no treatment interruptions because of tox-
icity. All patients completed the radiotherapy course having 
received the planned dose. All patients experienced grade 1/2 
nausea/vomiting, and 12 (43%) developed grade1/2 fatigue.
FIGURE 1.  Planning target volume includes all areas of pre-
operative pleural surfaces and thoracotomy scars. A dummy 
structure, representing the central part of the treated lung, 
is also delineated, helping optimization of planning. This is 
defined as the lung parenchyma located more than 2 cm 
internal to the pleural surface.
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Five of the 28 patients (17.8%) experienced severe 
respiratory symptoms within 5 months after the completion 
of radiotherapy, corresponding to grade 2 pneumonitis in 
three cases, and grade 3 pneumonitis in two cases. No fatal 
respiratory toxicity was reported.
Contralateral lung V5 was strongly correlated with 
the risk of pneumonitis. Patients who developed grade 2 
and 3 pneumonitis had a higher contralateral lung V5 (mean 
V5=32%) than those without pneumonitis (mean V5=17%) 
(p = 0.02). Other significant dosimetric parameters for total 
lung, contralateral lung, treated lung, and central portion of 
the treated lung (dummy structure) are reported in Table 2. 
Two other grade 3 toxicities were registered—one patient 
experienced a severe pain to the chest wall, which required 
narcotics administration, and one patient developed a severe 
thrombocytopenia. There were no cases of grade 3 esophagi-
tis. No rib fractures were documented. Relevant normal tissue 
dosimetric data are reported in Table 3.
DISCUSSION
We reported the toxicity results of a prospective study 
in which tomotherapy was used to deliver radical doses of 
radiation to the hemithorax with the intact lung, after radi-
cal P/D or surgical staging for MPM. This treatment resulted 
in a well-tolerated regimen: only two of the 28 patients (7%) 
developed a grade 3 pneumonitis within 5 months after the 
completion of the radiation therapy course, and no fatal pneu-
monitis was reported.
This low toxicity profile might be explained by the dosi-
metric data obtained. Two robust predictors of radiation pneu-
monitis are mean lung dose (MLD) and lung V20 (the volume 
of normal lung exceeding 20 Gy).6,7 In general, MLD values of 
less than 20 Gy and lung V20 values of less than 37% produce 
acceptable rates of pneumonitis after radiation therapy for non–
small-cell lung cancer. The median MLD and median lung V20 
reported in our study were 20 Gy and 37%, respectively.
In our series, patients who developed grade 2 and 3 
pneumonitis had a higher contralateral lung V5 (median 
V5=32%) compared with those without pneumonitis (median 
V5=17%). These data confirm the importance of the low 
dose of radiation in the pathogenesis of radiation pneumoni-
tis. These results support the hypothesis that the lung volume 
completely spared from irradiation determines the risk of 
radiation pneumonitis.8 The importance of low doses of radia-
tion delivered to the contralateral (remaining) lung has been 
emphasized in recently published articles. The study by Allen 
et al.9 reported that six of the 13 patients who underwent EPP 
after hemithoracic IMRT developed grade 5 pneumonitis. The 
most likely explanation for this increased pulmonary toxic-
ity was the dose–volume effects of the IMRT on the contra-
lateral lung, even though it was unclear which of the various 
lung dose–volume histograms metrics, including lung V5, 
best predicted for pneumonitis. The M.D. Anderson Cancer 
Center experience showed that patients who developed fatal 
pneumonitis had higher MLD, lung V20 and V5 than those 
patients without pneumonitis.10 Even if with a small sample 
size, the Duke University study reported a higher lung V5 in 
patients who developed lung toxicity.11 It must be noted that 
all these studies found dosimetric parameters correlating with 
pneumonitis in MPM patients who underwent EPP after hemi-
thoracic IMRT. Our study is the first one to determine the cru-
cial role of low doses of radiation to the contralateral lung in 
MPM, who underwent lung-sparing surgery, including radical 
P/D and biopsy, after hemithoracic radiotherapy.
The feasibility of treating the intact lung with pleural 
IMRT was recently reported by the researchers of the Memorial 
Sloan-Kettering Cancer Center.12 Thirty-six MPM patients 
were treated with a median radiation dose of 46.8 Gy (range, 
41.4–50.4 Gy). Seven patients (20%) experienced grade 3 
or worse pneumonitis (including a possible toxicity-related 
death). This toxicity profile is therefore comparable with that 
reported in our study, although we delivered higher radiation 
doses to the hemithorax (minimum radiation dose of 50 Gy).
Steroids and antibiotics were administered to all treated 
patients. Antimicrobial prophylaxis might be able to prevent 
bacterial pneumonia in patients who may have an hypoventila-
tion of the treated lung and limitation of cough reflex because 
of opioid analgesics, although steroids are administered 
with an anti-inflammatory intent. Whether this approach can 
TABLE 1.  Patient and Tumor Characteristics (n=28)
Age Median (yr) 68 (44–83)
Sex
Male 25
Female 3
Performance status
0–1 17
2 11
Laterality
Right 16
Left 12
Surgery
P/D 20
Biopsy 8
Histology
Hepitelioid 25
Nonhepitelioid 3
Stage
I 4
II 6
III 17
IV (T4) 1
Nodal status
N0 22
N 1-2 6
Preradiotherapy PFT (mean values)
FEV1, predicted (%) 74
DLCO, predicted (%) 67
PFT, pulmonary function test; P/D, pleurectomy/decortication; FEV1, forced 
expiratory volume in the first second; DLCO, diffusion capacity of the lung for carbon 
monoxide. 
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prevent possible acute respiratory symptoms cannot be dem-
onstrated, but detrimental effects are unlikely.
Our study has some limitations. First, although the 
median age was 68 years, the majority of the treated patients 
had a good performance status, and this could explain why the 
proposed radiation treatment was well tolerated. Second, the 
small sample size might have underestimated the rate of other 
severe complications.
In conclusion, we have shown that helical tomotherapy 
allows the safe delivery of high doses of radiation to the 
TABLE 3.  Relevant Normal Tissue Dosimetric Data (Mean Values)
Spinal Cord
Maximum dose 39 Gy
Esophagus
Mean dose 28 Gy
Liver
V30 for right treated lung 38%
V30 for left treated lung 1%
Ipsilateral kidney
V30 26%
Contralateral kidney
V15 51%
FIGURE 2.  Treatment profile.
TABLE 2.  Dosimetric Parameters (Mean Values) and Clinical 
Pneumonitis
CP (−)(n=23) CP (+)(n=5) p
Treated lung
V13 100% 100% n.s.
V20 97% 97% n.s.
V30 88% 88% n.s.
Mean dose 46 Gy 46 Gy n.s.
Contralateral lung
V5 17% 33% 0.02
Mean dose 4 Gy 5 Gy n.s.
Total lung (treated + contralateral)
V13 38% 40% n.s.
V20 36% 38% n.s.
V30 33% 34% n.s.
Mean dose 20 Gy 21 Gy n.s.
Central portion of the treated lung
(dummy structure)
V20 90% 90% n.s.
V30 59% 54% n.s.
Mean dose 33 Gy 33 Gy n.s.
V5, V13, V20, V30 indicates the normal tissue volume receiving more than 5, 13, 
20 and 30 Gy, respectively. CP, clinical pneumonitis; n.s., not significant. 
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hemithorax of MPM patients with intact lung. The question 
whether this therapeutic strategy might have a prognostic 
impact remains to be answered. Clinical outcome in terms 
of local control and survival will be reported with longer 
follow-up.
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